|
Imlunestrant Clinical Trials
3 actively recruiting trials across 2 locations
▼ -1 trial since September 2026
Also known as: Inluriyo, LY 3484356, LY-3484356, LY3484356, SERD LY3484356 +1 more
Pipeline
Phase 2: 2Phase 1/2: 1
Top Sponsors
- Eli Lilly and Company2
- Jonsson Comprehensive Cancer Center1
Indications
- Breast Cancer3
- Cancer3
- Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma1
- Localized Estrogen Receptor-Positive Breast Carcinoma1
- Solid Tumors, Adult1
Los Angeles, California2 trials
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ellison Clinic at Saint John's
Phase 1/2
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
UCLA / Jonsson Comprehensive Cancer Center
Phase 2
Birmingham, Alabama1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.